SNORD114-3: A Potential Drug Target for Various Diseases (G767579)

Target Name: SNORD114-3

NCBI ID: G767579

SNORD114-3

Other Name(s): 14q(II-3) | Small nucleolar RNA, C/D box 114-3 | small nucleolar RNA, C/D box 114-3

SNORD114-3: A Potential Drug Target for Various Diseases

SNORD114-3 (14q(II-3)) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has led to a gain of function in the gene, resulting in the production of a hyperactive protein that can cause a range of negative symptoms.

The 14q region of the chromosome is a key location for the development of many diseases, including leukemia, lymphoma, and neurodegenerative disorders. SNORD114-3 is a gene that is located within this region and has been implicated in the development of various diseases.

The gene encodes for a protein known as SNORD114, which is a zinc finger transcription factor. This protein plays a role in regulating gene expression and has been shown to be involved in the development and progression of many diseases.

One of the most significant aspects of SNORD114-3 is its role in the development of cancer. Cancer is a disease that can be caused by a variety of factors, including genetic mutations, expression of oncogenic genes, and changes in gene expression. SNORD114 has been shown to play a role in the development of many types of cancer, including breast, ovarian, and prostate cancer.

In addition to its role in cancer, SNORD114 has also been linked to the development of neurodegenerative diseases. These diseases are characterized by a progressive loss of brain cells and can include a range of disorders, including Alzheimer's, Parkinson's, and Huntington's diseases. SNORD114 has been shown to be involved in the development and progression of these diseases, and may be a potential drug target or biomarker for these conditions.

SNORD114 has also been linked to autoimmune disorders, which are a group of diseases in which the immune system attacks the body's own tissues or systems. These disorders can include rheumatoid arthritis, lupus, and multiple sclerosis. SNORD114 has been shown to be involved in the development and progression of these disorders, and may be a potential drug target or biomarker for these conditions as well.

In conclusion, SNORD114-3 is a gene that has been identified as a potential drug target or biomarker for a range of diseases. Its unique genetic mutation and involvement in the development of cancer, neurodegenerative diseases, and autoimmune disorders make it an attractive target for research and development of new treatments. Further studies are needed to fully understand the role of SNORD114-3 in these diseases and to determine its potential as a drug or biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 114-3

The "SNORD114-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets